Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer findings from F. Bourque and co-researchers published
May 19th, 2009
"Tamoxifen is a first-generation selective estrogen-receptor modulator that has been shown to decrease recurrence and prolong survival among premenopausal women with breast cancer; however, it also results in estrogen-insufficiency symptoms, the most common being hot flushes. The authors present a case in which tamoxifen apparently produced acute depression symptoms in a 34-year-old breast cancer patient," investigators in Montreal, Canada report. "After two aborted periods of tamoxifen treatment, the patient was started on venlafaxine as a preventive measure before tamoxifen treatment was begun again. After 2 months of treatment with venlafaxine, tamoxifen was...
Source: Cancer Weekly (2009-05-19)
|
